STSA
Income statement / Annual
Last year (2022), Satsuma Pharmaceuticals, Inc.'s total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2022, Satsuma Pharmaceuticals, Inc.'s net income was -$69.16 M.
See Satsuma Pharmaceuticals, Inc.’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
| Period Ended |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
| Operating Revenue |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Cost of Revenue |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Gross Profit |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Gross Profit Ratio |
0 |
0 |
0 |
0 |
0 |
0 |
| Research and Development
Expenses |
$44.09 M
|
$37.64 M
|
$36.27 M
|
$24.20 M
|
$6.43 M
|
$4.19 M
|
| General & Administrative
Expenses |
$15.13 M
|
$13.53 M
|
$12.06 M
|
$4.69 M
|
$1.08 M
|
$754,000.00
|
| Selling & Marketing
Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$15.13 M
|
$13.53 M
|
$12.06 M
|
$4.69 M
|
$1.08 M
|
$754,000.00
|
| Other Expenses |
$11.73 M |
$0.00 |
$0.00 |
-$1,000.00 |
$0.00 |
$0.00 |
| Operating Expenses |
$59.22 M |
$51.17 M |
$48.33 M |
$28.88 M |
$7.52 M |
$4.95 M |
| Cost And Expenses |
$59.22 M |
$51.17 M |
$48.33 M |
$28.88 M |
$7.52 M |
$4.95 M |
| Interest Income |
$905,000.00 |
$157,000.00 |
$1.12 M |
$1.19 M |
$72,000.00 |
$30,000.00 |
| Interest Expense |
$13,000.00 |
$163,000.00 |
$350,000.00 |
$482,000.00 |
$90,000.00 |
$15,000.00 |
| Depreciation &
Amortization |
$12.63 M
|
$550,000.00
|
$1.12 M
|
$1.19 M
|
$57,000.00
|
$10,000.00
|
| EBITDA |
-$58.31 M
|
-$50.62 M
|
-$47.21 M
|
-$27.69 M
|
-$7.20 M
|
-$5.15 M
|
| EBITDA Ratio |
0 |
0 |
0 |
0 |
0 |
0 |
| Operating Income Ratio
|
0
|
0
|
0
|
0
|
0
|
0
|
| Total Other
Income/Expenses Net |
$892,000.00
|
-$6,000.00
|
$765,000.00
|
$706,000.00
|
$169,000.00
|
-$225,000.00
|
| Income Before Tax |
-$70.06 M |
-$51.17 M |
-$47.56 M |
-$28.18 M |
-$7.35 M |
-$5.17 M |
| Income Before Tax Ratio
|
0
|
0
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
-$892,000.00 |
$92,000.00 |
$111,000.00 |
$340,000.00 |
$259,000.00 |
-$210,000.00 |
| Net Income |
-$69.16 M |
-$51.26 M |
-$47.67 M |
-$28.52 M |
-$7.35 M |
-$5.17 M |
| Net Income Ratio |
0 |
0 |
0 |
0 |
0 |
0 |
| EPS |
-2.16 |
-1.76 |
-2.74 |
-4.86 |
-1.86 |
-0.76 |
| EPS Diluted |
-2.16 |
-1.76 |
-2.74 |
-4.86 |
-1.86 |
-0.76 |
| Weighted Average Shares
Out |
$32.02 M
|
$29.17 M
|
$17.41 M
|
$5.86 M
|
$3.94 M
|
$6.80 M
|
| Weighted Average Shares
Out Diluted |
$32.02 M
|
$29.17 M
|
$17.41 M
|
$5.86 M
|
$3.94 M
|
$6.80 M
|
| Link |
|
|
|
|
|
|
